Journal of Clinical Oncology
Articles in this Issue
Geographic and demographic differences in genomic testing and outcomes in pancreatic cancer.
e22629 Background: National Comprehensive Cancer Network (NCCN) guidelines recommend universal tumor genomic profiling for...
Efficacy and dosimetry of yttrium-90 radiation segmentectomy for unresectable hepatocellular carcinoma: A retrospective study in China.
e14555 Background: Radiation segmentectomy (RS) with yttrium-90 ( 90 Y) microspher...
Living after lymphoma: A retrospective study of survivorship outcomes from a tertiary cancer centre in rural India.
e24130 Background: With improving survival in lymphoma, long-term treatment-related complications have emerged as a major...
Vimseltinib vs. pexidartinib: An indirect comparison of response rate in the treatment of tenosynovial giant cell tumor.
e23567 Background: Tenosynovial giant cell tumor (TGCT) is a locally aggressive but rare neoplasm of the synovium, tendon...
Preclinical efficacy of the anti-EBV agent brincidofovir (BCV) in EBV-associated gastric carcinoma (EBVaGC).
4028 Background: Immune checkpoint inhibitor (ICI) plus chemotherapy is an approved therapy for EBVaGC whose tumors expres...
INB-200: Phase I study and characterization of gene-modified autologous gamma delta (γδ) T cells in newly diagnosed glioblastoma multiforme (GBM).
2077 Background: Cell therapy for glioblastoma (GBM) holds promise but previous studies have not demonstrated durable resp...
ctDNA MRD combined with CODEX2 to identify high-risk colorectal cancer with potential sensitivity to immunotherapy.
e15664 Background: Circulating tumour DNA (ctDNA)-based minimal residual disease (MRD) detection identifies colorectal can...
Symptom monitoring program linked to electronic referrals (SyMPLER): A single-arm pilot feasibility study of remote symptom monitoring with palliative care self-referral.
TPS12164 Background: Symptoms often fluctuate during an individual’s cancer trajectory, and this can impact patients’ heal...
The efficacy and limitations of artificial intelligence (AI) in radiologic tumor assessment.
e20002 Background: Numerous Artificial Intelligence (AI) models for evaluating radiologic images are emerging, yet limited...
Accessibility of study contact information in ClinicalTrials.gov: A comprehensive analysis.
1534 Background: While the official purpose of ClinicalTrials.gov is to satisfy regulatory requirements from the U.S. Food...
Prognostic implications of HPV-related nasopharyngeal carcinoma in non-endemic regions: A meta-analysis.
e18147 Background: The cancerogenic role of the Epstein Barr Virus (EBV) is well established in endemic non-keratinizing n...
Treatment-interrupting hospitalization as an acute oncologic toxicity in solid tumors.
e23204 Background: Treatment-interrupting hospitalization (TIH) refers to unplanned admissions disrupting systemic cancer...
The impact of various radiation therapy options on plasminogen activation markers in the blood of patients with metastatic brain lesions.
2025 Background: Metastatic brain disease (MBD) is found in almost a third of patients with malignant neoplasms and is cha...
The role of rhamnose derived from gut microbiome in modulating the efficacy of non-small cell lung cancer immunotherapy.
e14586 Background: In recent years, the relationship between gut microbiota and metabolites and immunotherapy for non-smal...
Hepatic arterial infusion chemotherapy combined with immunotherapy for unresectable intrahepatic cholangiocarcinoma: A single-arm, open-label, prospective clinical trial.
2600 Background: In recent years, immune checkpoint inhibitors (ICIs) have demonstrated substantial clinical advances in t...
Clinical and translational study of YBX1 as a biomarker and therapeutic target in bone metastasis of non–small cell lung cancer.
e20574 Background: Bone metastasis in non-small cell lung cancer (NSCLC) is associated with poor prognosis and immunosuppr...
Genomic and immunogenomic characteristics of <i>KRAS</i> -altered ovarian cancer in a Chinese real-world cohort: Implications for precision therapy in the era of KRAS inhibitors.
e17589 Background: With the recent approval of the KRAS pathway–targeted combination of avutometinib and defactinib for lo...
Genomic and transcriptomic correlates of HER3 expression in prostate cancer.
3142 Background: HER3 ( ERBB3 ) is a key receptor in prostate cancer (PC) that sig...
Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)─directed antibody-drug conjugate (ADC), plus pembrolizumab: Updated results from the phase 1 study (SGNB6A-001).
8522 Background: IB6 is overexpressed in many tumors, such as non-small cell lung cancer (NSCLC) and head and neck squamou...
Four decades of population-based cancer incidence trends in Costa Rica: Implications for cancer surveillance in Central America.
e22551 Background: Reliable population-based cancer incidence data are essential for guiding cancer control strategies and...
Barriers and facilitators to implementation of evidence-based depression and distress treatment in adult oncology: A systematic review.
e13588 Background: Depression and psychological distress are common among cancer patients and are associated with increase...
The global burden of thyroid cancer from 1990 to 2023, with forecasts to 2050.
e22611 Background: Thyroid cancer is an important contributor to global health burden. Comprehensive and comparative estim...
First-in-human study of ALK201, a FGFR2b-targeting antibody-drug conjugate (ADC) for patients (pts) with advanced solid tumors.
3025 Background: ALK201 is a novel ADC comprising of an anti-FGFR2b humanized monoclonal antibody conjugated to topoisomer...
Bone mineral density changes in patients treated with anti-PD-1 immune checkpoint inhibitors.
12107 Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment (tx), with almost half of all c...
Real-world efficacy and safety of tarlatamab in extensive-stage small-cell lung cancer: A single-center retrospective study at university of Missouri.
e20150 Background: Tarlatamab is a standard second-line treatment for extensive-stage small cell lung cancer (ES-SCLC); ho...